Evidence for a stimulatory role of follicle-stimulating hormone on the spermatogonial population in adult males.
OBJECTIVE
To evaluate the effects of treatment with FSH on seminal indices and on the seminiferous epithelium of oligozoospermic subjects with normal FSH plasma levels.


METHODS
Placebo-controlled, double-blind randomized study.


METHODS
Academic setting.


METHODS
Ninety subjects with idiopathic oligozoospermia (sperm count of < 10 x 10(6)/mL) and normal plasma levels of FSH.


METHODS
Three months of treatment with FSH (60 patients) or placebo (30 patients); bilateral testicular fine-needle aspiration.


METHODS
Seminal indices; testicular cytologic features; plasma levels of FSH, LH, and testosterone; and ultrasonographic testicular examination.


RESULTS
According to seminal indices, patients treated with FSH and placebo were classified as nonresponders or as responders (as determined by at least a doubling of sperm count). No placebo-treated patients responded to treatment. Among FSH-treated patients, 20 responded to hormonal treatment and 40 did not. The results of pretreatment cytologic examination of testicular specimens from patients who did not respond to FSH treatment were consistent with hypospermatogenesis associated with maturational disturbances at the spermatid level. In contrast, patients who responded to treatment with FSH had isolated hypospermatogenesis without maturational disturbances. After FSH therapy, we detected an increase of spermatogonia and spermatocyte population in both the responder and nonresponder subjects. This increase was associated with an activation of spermatogenic and spermiogenic processes and with a rise in ejaculated sperm concentration only when isolated hypospermatogenesis was present (responder patients).


CONCLUSIONS
The findings of this study demonstrate that FSH treatment increases the spermatogonial population in men. This treatment may be appropriate for oligozoospermic subjects who have normal FSH plasma levels and a testicular evaluation characterized by hypospermatogenesis without maturational disturbances.
Foresta
C
C
Clinica Medica 3, University of Padova, Italy. FORESTAC@PROTEC.IT
Bettella
A
A
Ferlin
A
A
Garolla
A
A
Rossato
M
M
D000328:Adult; D015331:Cohort Studies; D004311:Double-Blind Method; D005640:Follicle Stimulating Hormone / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009845:Oligospermia / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D012016:Reference Values; D013091:Spermatogenesis / Q000187:drug effects* / Q000502:physiology; D013093:Spermatogonia / Q000166:cytology / Q000187:drug effects*; D013094:Spermatozoa / Q000166:cytology / Q000187:drug effects; D016896:Treatment Outcome; D014463:Ultrasonography
D005640:Follicle Stimulating Hormone